Advances and practical use of monoclonal antibodies in multiple myeloma therapy
Authors:
- 2 December 2016
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2016 (1) , 512-520
Abstract
The use of proteasome inhibitors and immunomodulatory agents in the treatment of myeloma have resulted in significant improvements in patient outcomes over the last decade. Although these agents now form the backbone of current myeloma treatment regimens both in the frontline and in a relapsed setting, drug resistance remains an inevitable challenge that most patients will encounter during their disease course. Hence, new treatment strategies continue to be explored, and the recent regulatory approvals of the monoclonal antibodies (mAbs) daratumumab (DARA) and elotuzumab (ELO), which target the plasma cell surface proteins CD38 and signaling lymphocytic activation molecule F7 (SLAMF7), respectively, have heralded the long-awaited era of antibody-based approaches in the treatment of myeloma. Hoping to build on these advances, a number of other mAbs are in various stages of clinical development, including those targeting myeloma cell surface antigens, the bone marrow microenvironment, and immune effector T cells such as anti-programmed cell death protein 1 antibodies. In this review, the current landscape and practical use of mAb-based therapy in myeloma will be discussed.Keywords
This publication has 34 references indexed in Scilit:
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialThe Lancet, 2016
- Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era beginsLeukemia & Lymphoma, 2015
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaNew England Journal of Medicine, 2015
- Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2015
- Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesLeukemia, 2015
- A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple MyelomaClinical Cancer Research, 2015
- Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and BortezomibBlood, 2014
- Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD74 monoclonal antibody) in relapsed or refractory multiple myelomaBritish Journal of Haematology, 2013
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaBlood, 2012
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008